Fraiser Kansteiner

As the U.S. focuses on beefing up its biopharma manufacturing infrastructure this year, a similar effort toward improved drug shortage resilience has been playing out across the pond. | Tuesday, the European Council gathered behind new regulations that seek to diversify local biopharma supply chains, support collaborative drug procurement models and devise incentives to bolster drug production in the bloc.

Artificial intelligence chemistry outfit Excelsior Sciences is gaining ground on its quest to hasten the discovery and production of small molecules. | Excelsior Sciences, which spun out of investment firm Deerfield Management, has roped in $95 million to scale its chemical synthesis "smart bloccs" platform, invest in its internal pipeline and forge partnerships across the industry, including in therapeutics and materials science.

Even as moving tariff targets and a capricious market have injected uncertainty into the operations of many biopharma players this year, it’s hard to deny the effect that President Donald Trump’s t | Even as moving tariff targets and a capricious market have injected uncertainty into the operations of many biopharma players this year, it’s hard to deny the effect that President Donald Trump’s trade duties have had on industry investment in the U.S.

The Trump administration has lined up another country-specific trade agreement, this time with the U.K., which confers Washington’s biggest break on pharmaceutical import tariffs yet. | The Trump administration has lined up another country-specific trade agreement, this time with the United Kingdom. The agreement confers Washington’s biggest break on pharmaceutical import tariffs yet.

The FDA has opened an investigation into Takeda’s recombinant protein med Adzynma following the reported death of a pediatric patient who received the drug. | The FDA has opened an investigation into Takeda’s recombinant protein med Adzynma following the reported death of a pediatric patient who received the drug.

Some four years into Jemperli’s commercial life span, a rift has emerged between GSK subsidiary Tesaro and the potential cancer blockbuster’s original developer, AnaptysBio. | Some four years into Jemperli’s commercial life span, a rift has emerged between GSK subsidiary Tesaro and the potential cancer blockbuster’s original developer, AnaptysBio.

After several notable moves to grow the reach of its biomanufacturing platform in recent months, Antheia is linking arms with a pharmaceutical ingredient juggernaut in this field. | Antheia is teaming up with TAPI—Teva’s active pharmaceutical ingredient and contract manufacturing business—in a bid to further commercialize its pipeline of biosynthetic drug ingredients and key start materials.

Teva Pharmaceutical Industries is

Facing the fact that Lundbeck’s unexpected offer for Avadel Pharmaceuticals was sweeter, Alkermes has come back to the negotiating table with a higher bid it believes can seal the deal. | Alkermes and Avadel have reached an accord on a new offer that would see Alkermes pay up to $22.50 per Avadel share to acquire the company. Both drugmakers’ boards have blessed the amended deal and currently expect the acquisition, which values Avadel at up to $2.37 billion, to close in 2026’s first quarter.

Having found swift success with its Jazz Pharmaceuticals and BeOne Medicines-licensed cancer med Ziihera, Zymeworks has